Podcasts about approvals

We are talking Ghostbusters on the April 2024 Party in the Back Podcast. President of Business Operations from the Fort Wayne Komets Scott Sproat and Jon Long Manager the Event Presentation & Creative Content for the Edmonton Oil Kings join the podcast to talk about their success with this Movie theme night.Scott and Jon drop insights on all aspects of their promotion, including:Approvals and support from movie studio and rights holdersLeading their team's creative effortPopular fan elements for their Ghostbusters NightSocial Media elementsScoreboard additionsJersey Auctions, like the Komets $13,000 charity jersey auctionMusic and bumpers, including a one night change in the Oil Kings Goal songSponsor integrations and more...

First impressions are money in the service drive. In this episode of Dealer Talk with Jen Suzuki, we dig into the relational greeting — the difference between being just another transactional advisor and being the trusted pro customers return to again and again. I'll walk you through how to: Show up with the right energy (because customers feel it before you speak) Use names, humor, and personal touches to build instant trust Transition naturally from small talk to business without feeling “robo” Make customers feel like people, not VIN numbers Turn a check-in into the start of a relationship that drives approvals and loyalty This isn't theory — it's what I see working every week in dealerships. If your service team can nail this, the rest of the process gets easier, approvals go up, and income potential climbs. Dealer Talk with Jen Suzuki Podcast |

How do you get your executive pastor to give a "yes" to all your requests?We're joined by our Southeast Church friends today to continue our Executive Pastor and Tech podcast series. In this episode you'll hear: 1:00 Blake's hilarious church tech mic moment4:55 Southeast Christian Church team joins the podcast6:50 Five Truths and a Lie: church production edition16:00 What an executive pastor really does in church leadership18:30 How church techs can build trust with their executive pastor23:15 How to get a “yes” from your executive pastor as a church tech33:15 The right way to ask your executive pastor for resources or budget41:30 When church gear fails (and you warned it would)45:45 System failure stories in church production52:00 Why the church tech–integrator relationship matters1:01:00 Handling tension with your executive pastor as a church production leader1:07:10 Why church techs should talk about non-work things with pastorsCheckout HouseRight's solutions for your church and open jobs here. Resources for your Church Tech Ministry Sell Us Gear: Does your church have used gear that you need to convert into new ministry dollars? We can make you an offer here. Buy Our Gear: Do you need some production gear but lack the budget to buy new gear? You can shop our gear store here. Connect with us: Sales Bulletin: Get better deals than the public and get them earlier too here! Early Service: Get our best gear before it goes live on our site here. Instagram: Hangout with us on the gram here! Reviews: Leaving us a review on the podcast player you're listening to us on really helps the show. If you enjoyed this episode, you can say thank you with a review!

This one's for the service team (but sales, you should listen too—because everybody's in sales). In this kickoff to my new Service Team Series on Dealer Talk with Jen Suzuki, I break down the Service Cheat Code: how preparation before the customer even shows up changes everything. From reviewing history and declined work to checking recalls, parts, and notes, I share the exact steps that turn rushed, transactional check-ins into confident, relational experiences that win trust and drive approvals. These are the same hacks I train advisors on in dealerships every single week—practical, now, and proven to increase income potential. This episode is your game plan for better connections, smoother days, and higher CSI scores. Dealer Talk with Jen Suzuki Podcast |

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to feature a conversation about soft tissue sarcoma management. Drs Armstrong and Tawagi discussed that soft tissue sarcomas represent a rare and heterogeneous group of malignancies that arise from mesenchymal cells rather than epithelial cells and encompass several distinct histologic subtypes. They explained that although uncommon, these sarcomas are frequently emphasized in board examinations, partly because their management has historically been stable, though recent FDA approvals and ongoing research have expanded therapeutic options. They noted that risk factors may include prior radiation exposure, environmental agents, and viral infections. Additionally, they shared that chronic lymphedema is associated with angiosarcoma, whereas rare hereditary syndromes may predispose individuals to specific sarcoma subtypes.  Clinically, they explained that sarcomas may arise anywhere in the body, though many occur in the thigh, buttocks, or groin, typically presenting as painless, enlarging masses often mistaken for benign lesions. They emphasized that diagnosis requires core needle biopsy to preserve tissue architecture and that staging relies on MRI of the primary site and CT of the chest, given the strong predilection for pulmonary metastases. They also summarized the five subtypes of soft tissue sarcoma—synovial, clear cell, angiosarcoma, rhabdomyosarcoma, and epithelioid. They reported that the cornerstone of localized disease management is surgical resection, preferably limb-sparing when feasible, combined with radiation for larger or high-risk tumors. They also highlighted novel strategies like immunotherapy. For metastatic disease, they stated that surgical resection of pulmonary metastases can achieve durable remissions in select patients. 

Buy here, pay here dealership Oak Motors is slowing approval of credit applications as long-term affordability concerns persists and despite increased volume.  Anderson, Ind.-based Oak Motors' applications were up 30% year over year at the beginning of September, according to data the dealership group provided to Auto Finance News. The dealership group did not specify the number of applications. The increase comes despite a drop in sales and amid a decline in approvals at the dealership group, which has five locations in Indiana, Executive Board Member Tiger Okeley told AFN. “We've seen about a 20% decrease in sales, and that's by design,” he said, without providing specific sales numbers. Oak Motors focuses on identifying consumers who can commit to long-term deal structures that are beneficial to the consumers and the dealership, he said.  While the BHPH dealership sells as many vehicles as it wants to sell, success depends on finding customers capable of keeping up with weekly payments, Okeley said.  “If they stop paying us, it didn't matter if we sold them a car,” he said. The bottom line is “we didn't get paid.”  BHPH is attractive to customers with risky credit profiles or those who don't have access to traditional financing, Okeley said. Some BHPH dealerships offer customers a chance to rebuild their credit to qualify for traditional financing down the road. In fact, an inaugural survey of 1,015 consumers across the country published by Oak Motors on Aug. 15 revealed that 32% of consumers avoided applying for an auto loan due to concerns about their credit score this year.  Hear more about Oak Motor's credit survey results, market trends and the state of the buy here, pay here market in this week's podcast. This episode is sponsored by The Work Number by Equifax. Auto Finance Summit, the premier industry event for auto lending and leasing, returns Oct. 15-17 at the Bellagio Las Vegas. Learn more about the 2025 event and register here. 

In this Australian Property Podcast episode, your hosts Pete and Owen talk about the top news stories of the week, along with some listener questions  Topics covered today   - First homebuyer scheme – early movers?  - Fastest home price increase in 15 months (0.7% in August)  - Rethinking the housing pipeline  - Listener Q&A  Episode Resources  - Government incentives upending the property market⁠⁠  - Impact on property prices of expansion of first home guarantee⁠⁠  - 5% deposit scheme to begin in October ⁠⁠  - Capitals overtake regions after a 9-month run⁠⁠   ⁠- Approvals ease, but pipeline is solid⁠⁠ - More approvals, more problems? Rethinking the housing pipeline⁠⁠ - Government fast-tracks 5% deposit scheme for first-home buyers - Home prices lift on tight buying - Housing values bloom ahead of spring selling season Rask Resources  - Pete's Buyers Agency⁠  - Alcove mortgage broking⁠  - Amy Lunardi Buyers Agency (Melbourne)⁠  - All services⁠  - Financial Planning⁠  ⁠- Invest with us⁠  - Access Show Notes⁠ ⁠ - Ask a question ⁠ DISCLAIMER: This podcast contains general financial information only. That means the information does not take into account your objectives, financial situation, or needs. Because of that, you should consider if the information is appropriate to you and your needs, before acting on it. If you're confused about what that means or what your needs are, you should always consult a licensed and trusted financial planner. Unfortunately, we cannot guarantee the accuracy of the information in this podcast, including any financial, taxation, and/or legal information. Remember, past performance is not a reliable indicator of future performance. The Rask Group is NOT a qualified tax accountant, financial (tax) adviser, or financial adviser. Access The Rask Group's Financial Services Guide (FSG): https://www.rask.com.au/fsg Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Robert F. Kennedy Jr. faced the Senate Finance Committee in a tense hearing amidst calls for the removal of the health secretary. The committee questioned Kennedy on his recent actions, including the firing of CDC director Susan Monarez. Meanwhile, the FDA's new rare disease pathway received mixed reactions, with some questioning its tangible impacts. AC Immune downsized and refocused its pipeline, while Kennedy proposed adding seven new vaccine advisors to the ACIP. Other news included successful RNA editing in an AATD study, demands for YouTube to remove anti-vaccine videos, and a new framework for rare disease approvals by the FDA. Thank you for tuning in to today's episode of Pharma and Biotech daily.

We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex's new pact with Enlaza for autoimmune disease—which the Casgevy maker hopes could ease conditioning for the sickle cell/beta thalassemia gene therapy—and Novartis' agreement with Arrowhead for neurodegenerative diseases such as Parkinson's.  But as we look ahead, Thursday's Senate Finance Committee will be the focus this week, as Health and Human Services Secretary Robert F. Kennedy Jr. will answer questions after the ousting of CDC Director Susan Monarez. Her departure is reportedly linked to changes to the regulation of COVID-19 vaccines, for which the FDA last week issued restricted approvals to Moderna, Pfizer/BioNTech and Novavax and rescinded the emergency use authorizations. The next ACIP meeting—where COVID-19 vaccines will be on the agenda—is set for Sept. 18 and 19.   In the weight loss arena, Novo Nordisk presented results from a real-world study this weekend at the European Society of Cardiology Congress in Madrid showing that Wegovy cut the risk of heart attack, stroke or death by 57% compared to Eli Lilly's tirzepatide in people with obesity and cardiovascular disease. The company also continues to throw money into the space, last week inking a $550 million deal with Replicate for RNA-based treatments for obesity and diabetes. Meanwhile, Lilly is dropping studies of one oral obesity candidate as another nears a regulatory filing. Finally, the FDA greenlit the first GLP-1 generic for obesity.   We also discuss reactions to the FDA's new guidance on radiopharma drug development, four recent approvals for rare diseases, and everything you ever wanted to know about SPACs. 

In this episode of the Residential Developer Podcast, Nathan unpacks NSW's new pattern design books and what they mean for duplex and semi-detached projects. With a fast-track CDC approval pathway, eligible developments on 12m frontages and 450m² lots can now be approved in as little as ten days.Nathan compares the two design options, Semi 01 and Semi 02, covering their key differences in size, flexibility, and livability ratings. He also explains the strict compliance rules, facade limitations, and site constraints developers must watch out for.From subdivision opportunities to affordable housing outcomes, Nathan highlights both the opportunities and risks of this major planning shift.Topics: ✅ Fast-Track CDC Approvals✅ Minimum Lot & Size Rules✅ Semi 01 vs Semi 02✅ Flexibility & Adaptations✅ Subdivision Options✅ Key Risks & CaveatsConnect with Nathan Battishall:LinkedIn: https://www.linkedin.com/in/nathanbattishall/Website: www.duplexbuildingdesign.com Hosted on Acast. See acast.com/privacy for more information.

Up-to-date News and Sport. This is Your News Now.See omnystudio.com/listener for privacy information.

Automate common workflows, ensure accuracy, and free your time for higher-value work.Quick Tech TalkWith Steve YossCPE TodayFor years, QuickBooks Online (QBO) has been a go-to accounting platform for small and midsized businesses. Now, its Advanced Edition takes efficiency to a whole new level by introducing robust workflow automation features designed to eliminate repetitive tasks and keep financial professionals focused on what matters most. MORE Steve Yoss here | MORE TECH Imagine never having to manually send invoice reminders, route approvals, or post recurring journal entries again. With QBO Advanced, automation handles it for you. The platform now offers numerous automations to help you ensure accuracy, increase transparency, and allow you to focus on the work that means the most to you.

Following its 2024 overhaul, MM2H posted an 84% boost in inflows, including RM237 million in property and RM597 million in deposits.View the full article here.Subscribe to the IMI Daily newsletter here. 

In this episode of Wealth Coffee Chats, we break down the truth about pre-approvals—what they actually mean, how they affect your borrowing power, and the common mistakes to avoid. Learn how rate cuts, conditional approvals, and lender tech are changing the game for property buyers. Plus, find out what really matters before bidding at auction or locking in a deal.

US President Donald Trump signed the “Enabling Competition In The Commercial Space Industry” Executive Order (EO). Gilat Satellite Networks has been awarded a multimillion dollar contract by Israel's Ministry of Defense for the delivery and integration of satellite communication systems (SATCOM) and services. The Italian Space Agency (ASI) has signed an agreement with SpaceX for an uncrewed mission to Mars aboard a future Starship mission, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Luis Torres, founder of Torres Orbital Mining (TOM).  You can connect with Luis on LinkedIn, and find out more about TOM on their website. Selected Reading Enabling Competition in the Commercial Space Industry – The White House Gilat receives a multimillion contract from Israel's Ministry of Defense for advanced strategic defense SATCOM project Agenzia Spaziale ITA (@ASI_spazio) / X Spire Global Announces Preliminary Second Quarter 2025 Revenue and Provides Business Update KBR and Axiom Space Successfully Complete Initial Crewed Spacesuit Tests in NASA's Neutral Buoyancy Lab Space Kinetic Corp. LinkedIn This real 'Eye of Sauron' spits out ghost particles in space. Here's what it looks like T-Minus Crew Survey Complete our annual audience survey before August 31. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

‘Abundance v Sufficiency: Dawn of Justice' T-Shirt Edition With a sufficiency of sufficiency-themed t-shirts now on the streets, the universe is out of balance and your intrepid hosts need to balance the sufficiency yin with an abundance yang! And OH BOY did we have an abundance of abundance-themed t-shirt ideas for you. YOU need not have Abundance FOMO any longer. Run, don't walk to our merch page and grab the limited edition Abundance tee: www.letmesumup.net/p/merch/.—It's Productivity Palooza 2025 and invited to the hottest party in town (this here podcast of course) is the one and only Alison Reeve who joins your intrepid hosts in a Productivity Commission report launch party! Landing in Jim Chalmers' hot little hands before the big Economic Reform Roundtable in Canberra (the other hottest party in town), the PC's interim report, “Investing in Cheaper, Cleaner Energy and the Net Zero Transformation” has a grab bag of ideas: Adaptation - getting its moment, finally! Approvals - strike teams and make em' fast! Carbon pricing - safeguard harder! Also check out this excellent OpEd from Alison in the AFR.Our main courseI'm Wonky But I'm Worth It might have been the unofficial subtitle of the latest contribution to reform of the National Electricity Market by expert panel Tim Nelson, Paula Conboy, Ava Hancock and Phil Hirschhorn. That's right, your intrepid hosts evidently didn't have anything else to do last weekend than consume the 220-page elephant of the “National Electricity Market wholesale market settings review” draft report (we did, but we read it anyway – you're welcome). While heavy on financial jargon, we wonder whether this might be the political bullet proof vest this policy needs, lest the ESEM join the acronym soup grave of NEM review solutions past! Targeted upgrades to existing architecture across the spot market (visibility of DER!), medium-term derivatives (more liquidity via market-making obligations!) and long-term investment signals (enter, Electricity Services Entry Mechanism!) with a partridge in a pear tree and consumer reforms (the epilogue that Frankie thinks deserves a prologue). One more thingsTennant's One More Thing is: the greatest movie ever made!? WARNING: 3.5 hours and carbon monoxide poisoning awaits.Frankie's One More Thing is: a watching brief on the expert panel on atmospheric measurement of fugitive methane emissions in Australia, chaired by former chief scientist Dr Cathy Foley, and just how this might contribute to policy - Global Methane Pledge, ahem!Alison's One More Thing is: is the gas network problem solving itself? A Victorian gas utility helping customers go all-electric feels like cause for celebration in putting consumers first!Luke's One More Thing is: a shout out and salute to outgoing Clean Energy Council CEO Kane Thornton, for his tireless work supporting and leading the growth of Australia's renewables industry and for being an all-round awesome human. Go well and see you soon Kane!And that's it for now, Summerupperers. There is now a one-stop-shop for all your LMSU needs: head toletmesumup.netto support us on Patreon, procure merch, find back episodes, and leave us a voicemail!

Housing is on the agenda at next week's productivity roundtable, with the Treasurer wanting better regulation and faster approvals to build more homes.Mentioned in this episode:Sign up to The Conversation's newsletterhttps://theconversation.com/au/newsletters

Send us a textDominik Lysek, CEO of PharmaTrail, explains how blockchain technology can solve trust issues in clinical trials by providing an incorruptible audit trail that verifies data integrity. This solution could significantly accelerate the time required for regulatory approvals, partnerships, and acquisitions, ultimately getting treatments to patients faster.• Blockchain provides a complete, unchangeable audit trail where data can only be added, never deleted• Most clinical data (99.9%) has integrity, but proving this to outsiders is time-consuming and costly• PharmaTrail uses private blockchain technology alongside traditional databases for optimal security and functionality• Blockchain verification can maintain momentum through due diligence processes, preventing deals from stalling• The technology creates trust by enabling independent verification of data integrity• Current systems face challenges with data credibility that delay patient access to treatments• Private blockchains protect patient data while still providing the benefits of immutable record-keepingSupport the show________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Shoot us a Text.Episode #1118: Auto loan approvals are climbing as vehicle demand heats up, Jaguar doubles down on its high-dollar EV future, and a new survey shows U.S. shoppers are still splurging on impulse buys.Show Notes with links:New data shows consumers may finally be catching a break in the auto loan market. Approvals are up, interest in buying is growing, and middle-income shoppers are more willing to make sacrifices to keep their vehicles.The New York Fed says auto loan rejection rates dropped sharply in Q2 2025 to 6.7%, down from a painful 19% last year.14% sought a loan in the past year, and more expect to apply in the coming months.Santander's latest survey shows 55% of middle-income consumers plan to buy a vehicle in the next 12 months, the highest reading in two years.Tariff fears are real: 18% of respondents sped up a big purchase in Q2 because of price uncertainty, with 41% of those buying a vehicle.Santander says this is the first time in eight quarters that buyers outnumber those delaying a purchase — a sign pent-up demand could finally be turning into sales.Jaguar is set on an electric, ultra-luxury future. Despite some loud critics, the brand is preparing a bespoke EV platform and three six-figure models designed to take on the industry's elite.Incoming JLR CEO PB Balaji says the brand's EV strategy is locked in, with positive early feedback from customers.Production of all current Jaguars except the F-Pace ended last year as the company stockpiled inventory.First new model — the GT — is a sleek, 600-hp electric sedan with about 425 miles of range and a $150K price tag, expected late next year as a 2027 model.A large, three-row electric crossover will follow in late 2027 or early 2028.The third entry is rumored to be a large, ultra-luxury electric sedan aimed at Rolls-Royce and Bentley buyers, due around 2030.While many Americans say they're trying to rein in discretionary spending, a new survey shows the vast majority still made at least one unplanned purchase last month.Optimum Retailing survey finds 72% of Americans made an unplanned in-store discretionary purchase in the past month.While 34% plan to cut back in the next six months, sales events (55%), eye-catching displays (45%), and immediate availability (26%) make spending hard to resist.Only 5% said in-store shopping no longer feels “worth it.”Many shoppers are sticking to a budget by cutting dining/takeout (48%), clothing/accessories (44%), and electronics/gadgets (37%).“Consumers today are cautious, but not unengaged… The moment and experience must both feel correct,” said Sam Vise, CEO of Optimum Retailing.Join Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

Registered design practitioner Scott Pearse joins me to explain how “$2,000 pieces of paper” are creating a barrier for those wanting to add value to their apartment with a renovation. Plus, why it's less about the build and more about the politics. If you're planning a reno in strata, this episode is your reality check.

The newest wedge driving Canada and the U.S. apart? Skimmed milk powder, apparently. Like a straight-A high schooler whose grades drop at university, Health Canada is struggling with an increased workload.

Greg Brady spoke with Dr. Mike Moffatt, Economist, Founding Director, PLACE Centre. Co-Host, "Missing Middle" about, are the City of Toronto claimed improvements in housing application timelines real or an illusion? Learn more about your ad choices. Visit megaphone.fm/adchoices

Greg Brady spoke with Dr. Mike Moffatt, Economist, Founding Director, PLACE Centre. Co-Host, "Missing Middle" about, are the City of Toronto claimed improvements in housing application timelines real or an illusion? Learn more about your ad choices. Visit megaphone.fm/adchoices

The initial results are in for the pilot effort to improve the cloud security program known as FedRAMP, four vendors have crossed the finish line to receive low authorizations under FedRAMP, proving the faster process is working for more on how the General Services Administration plans to continue to improve FedRAMP, federal news networks executive editor Jason Miller joins me nowSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this second episode of the It's Public podcast, Antonella Pacitti, Jennifer Barron and Lizzie Knight discuss Australia's new mandatory merger notification regime, unpacking how the ACCC's major changes to competition approvals will impact dealmaking.Conversation focuses on:implications for cross-border deals which also require Foreign Investment Review Board (FIRB) approval. the increased regulatory risk and compliance challenges for deal completion, including how compatible Australia's markets are with "Hell or High Water" clauses requiring bidders to accept any regulatory conditions imposedimpacts for deal valuation in volatile markets the rise in national security-driven regulatory decision-making, especially in critical minerals. 

In this episode of ELI, we sit down with Dr. Angad Singh Bedi, the Managing Director of BCD Group, one of India's oldest and largest real estate conglomerates. Angad shares his unique perspective on the evolution of the Indian real estate market, from a family business rooted in pre-partition India to a professionally-run, zero-debt empire.Join us as we dive deep into the most pressing topics shaping the industry today:- The post-COVID shift in homebuyer priorities and the new definition of a 'home'.- How Gen Z is disrupting the property market with new demands.- The critical debate on Floor Space Index (FSI) and the future of urban development in cities like Mumbai and Bengaluru.- The rise of Tier-2 and Tier-3 cities and what's fueling their growth.- How the industry is tackling challenges like infrastructure strain and climate change.- The impact of technology, from PropTech and AI to 3D printing in construction.- Angad's vision for India's real estate landscape in 2040 and its journey to a multi-trillion dollar economy.Whether you're a prospective homebuyer, an industry professional, or simply interested in the future of Indian cities, this conversation provides an invaluable insider's view.Don't forget to Like, Share, and Subscribe for more insights from India's leading entrepreneurs!Chapters:(00:00) Introduction(00:24) Meet Angad: From Chartered Accountant to Real Estate Leader(02:16) The Legacy of BCD Group: A Zero-Debt Empire Built Across Decades(04:03) The Current State of Indian Real Estate: An Era of Maturity & Professionalism(05:58) Post-COVID Real Estate Trends & The New Definition of 'Home'(08:28) Beyond Square Footage: The Rise of Community-Centric Living(10:34) Gen Z Enters the Market: How Are Young Homebuyers Different?(12:32) The FSI Debate: Should Indian Cities Grow Vertically or Horizontally?(14:42) India's Untapped Potential: Real Estate Growth in Tier-2 & Tier-3 Cities(16:24) Climate Change & Infrastructure Collapse in Major Indian Metros(18:20) The Government's Role: How RERA & Policy are Shaping the Market(20:09) The True Cost of a Property: Land, Approvals, and a Developer's View(21:49) PropTech & Innovation: How Technology is Transforming Real Estate(24:30) Vision 2040: The Future of India's Multi-Trillion Dollar Real Estate Economy(25:48) Closing Remarks

JOIN THE MONEY MISSION:https://moneymissionja.comGet the Money Mission Workbook: https://amzn.to/4567eL2Planning for retirement is an important step in your wealth journey.But where do you start, and what do you need to do? We'll discuss.Then, the analysts weigh in on the latest market developments…Kingston Wharves just took a 27% stake in Cargo Handlers. What does that mean for shareholders?And NEPA has approved solar farms for Wigton and Sunterra. What's next?We'll discuss.******************OUR SEGMENTS: 0:00- Intro2:16- What's Hot in Business8:17- Discussion44:28- Market Recap49:47 - The Analysts- Kingston Wharves59:04 -The Analysts- NEPA approvals*******************SUBSCRIBE TO OUR NEWSLETTER: https://kalilahreynolds.com/newsletter JOIN THE MONEY MISSION:https://moneymissionja.com

Anton from Drop Ship Lifestyle addresses a common question regarding the difficulty of obtaining brand authorization using his dropshipping techniques. He details the process and shares tips for securing brand approval, highlighting the importance of building a strong brand presence for business growth. Learn about brand approval and how to make money online!

The Uptime hosts examine Interior Secretary Doug Burgum's federal oversight mandate, the administration's plan to replace Idaho's cancelled Lava Ridge Wind Farm with six nuclear reactors, and critique a recent wind conference in Australia. The discussion also covers French utility EDF's plan to sell 50% of its North American wind portfolio to raise 2 billion euros for nuclear upgrades in France. Sign up for the next SkySpecs webinar! Register for  UK Offshore Wind Supply Chain Spotlight 2025! Sign up now for Uptime Tech News, our weekly email update on all things wind technology. This episode is sponsored by Weather Guard Lightning Tech. Learn more about Weather Guard's StrikeTape Wind Turbine LPS retrofit. Follow the show on Facebook, YouTube, Twitter, Linkedin and visit Weather Guard on the web. And subscribe to Rosemary Barnes' YouTube channel here. Have a question we can answer on the show? Email us! Allen Hall: [00:00:00] Mark your calendars December 11th at the Royal Highland Center in Edinburgh, because you'll want to be at the UK offshore wind supply chain Spotlight 2025. This isn't just another conference. It's where the UK's offshore wind supply chain comes together. Co-hosted by ORE Catapult and the Offshore Wind Growth Partnership. Spotlight 2025 is where developers connect with suppliers and where the next breakthrough in offshore wind technology gets its moment to shine. So whether you're looking to forge new partnerships, secure critical investments, or simply stay ahead of the curve in this rapidly evolving sector, you'll need to register for this event. Remember December 11th in Edinburg for Spotlight 2025. Just Google. Edinburgh Supply Chain Spotlight 2025. You can register today. You're listening to the Uptime Wind Energy Podcast, brought to you by bill turbines.com. Learn train and be a part of the Clean Energy Revolution. [00:01:00] Visit build turbines.com today. Now here's your hosts, Alan Hall, Joel Saxon, Phil Tartaro, and Rosemary Barnes.  Allen Hall: Well, greetings from Charlotte, North Carolina to the Queen City. I'm Alan Hall and I'm here with Phil Tartaro from the Golden State of California. And Joel Saxon is at an undisclosed location in a secure bunker, so that's not gonna leak out where he is. And Rosemary is enjoying the winter months in beautiful Australia. And we have some interesting topics this week, but I wanna lead off with Rosemary. Went to another WIN conference, WIN plus conference in Australia. Rosemary.  Rosemary Barnes: Yeah, actually I, I feel petty, um, dissing this conference now because this is the one that Alan, you and I did a whole episode on how bad this conference was last year and, um. That's what caused us to feel like we needed to organize our own wind energy conference. Uh, that covered some technical topics, but you're walking around the conference, like, why is there so much hydrogen stuff at a wind energy conference? And I'm like, okay, well maybe that's like what they perceive that, you know, most of the [00:02:00] new projects in Australia, all the big ones say that they're associated with hydrogen. So maybe that's it. And then I started seeing a lot of, um, carbon capture things and, you know, like eels and all sorts of, all sorts of things related to. CO2. Um, so that confused me. Um, and then I saw that it was also a carbon capture conference too. So yeah, the exhibition was, was not, not too bad. I had definitely had lots of good conversations with people. Um, some interesting things like, um, the drone, uh, yeah, drone inspections, a few new capabilities coming up. There were a couple of people with good drones, um, that can. Test the resistance of an LPS and say that they can do a whole turbine in an hour and a half. So, um, that's, that's pretty good. There was also some cool NDT, uh, non-destructive testing stuff and a really small portable ultrasound machine, and they wouldn't give me a price,

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from July 12-18, 2025.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this special FDA-focused episode of Mind Moments, migraine expert Stewart Tepper, MD, professor of neurology at the Geisel School of Medicine at Dartmouth, discusses the recent FDA approvals of STS101 (Atzumi; Satsuma Pharmaceuticals) and CT-132 ( ) for the acute and preventive treatment of migraine. Tepper breaks down the pharmacological profile and clinical utility of DHE, the formulation behind STS101, and how the latest delivery innovations may expand its use in acute migraine care. He also dives into the approval data behind CT-132, the first-ever FDA-approved prescription digital therapeutic for migraine, and what it could mean for patients and clinicians alike. Tepper highlights the need for clinician education as novel therapeutics reshape the treatment landscape and offers insight into how these new tools could improve patient outcomes with fewer side effects and better accessibility. For more of NeurologyLive's coverage of STS101 and CT-132 for migraine, head here: FDA Approves STS101 Nasal Powder as New Treatment for Acute Migraine FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine Episode Breakdown: 1:10 – Overview of DHE, patient suitability, and STS101's place in treatment 6:05 – Efficacy and safety data from the ASCEND and SUMMIT trials for STS101 10:20 – The expanding migraine toolbox and need for clinician education 15:10 – CT-132's first-in-class status and clinical trial data 16:25 – Clinical use of CT-132 as an add-on preventive 19:30 – The knowledge gap on digital therapeutics and educating the neurology community 23:00 – Future directions and hopes for expanded CT-132 research Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

What do you get when you combine razor-sharp humour, social-first instincts, and a refusal to play by the rules?An equal-parts entertaining, and practical, deep dive into brand building on social today.This week, Verity sits down with Gabriel Gomez (Head of Social & Community @ MCoBeauty (US), Creator & Speaker) to explore how one of Australia's most-followed beauty brands is winning the US market. Spoiler alert: it's by moving fast, listening closely, and making the right kind of noise online.Turn this episode on and up to learn how to:Spot and Scale the Right Cultural Moments, Without 10 Approvals & a Deck: Gabe shares how MCoBeauty gets from idea to action in minutes, thanks to lean teams, shared instincts, and a refusal to overthink the feed.Build Campaigns with Cross-Functional Input (Without Slowing Things Down): Gabe's approach flips the usual script: involve people early, keep ideas fluid, and trust that great strategy can come from any level of the org.Choose Creators Based on Connection, Not Clout: Whether it's scouting emerging talent or inviting creators into the concepting process, Gabe breaks down how MCoBeauty treats creators like consultants, not content machines.Balance Viral Chaos with Brand Clarity (and Still Forget the Playbook): Social's a sprint, but that doesn't mean strategy gets lost. Learn how MCo blends brand consistency with bold, off-script moves that actually land.Build a Fast-Moving, Emoji-Powered Social Culture that Thrives Under Pressure: From skipping the decks to celebrating team wins with emphasis, Gabe shows how to lead a social team that runs on energy and impact.Decide What's a Green Flag (and What's a Giant Red One): In a rapid-fire game, Gabe shares exactly how he filters pitches, rates brand behaviour, and why he's definitely deleting your “$50 and a lipstick” offer.Plus: you'll hear why TikTok is their #1 Advocacy driver, how Gabe spots red-flag creators, and the surprising platform he opens first every day.His advice is fast, fresh, and unapologetically honest – just like the brands that win on social now.Chapters00:00 – Gabe Gomez & the MCoBeauty Mindset03:00 – Why Dupes, Not Decks, Drive Beauty Culture Now07:00 – Crashing Trends & Creating Chaos: Moving at the Speed of Social12:00 – F*** the Playbook: Balancing Strategy with Spontaneity17:00 – Creators as Consultants: Rethinking Influence & Partnerships22:00 – The Green Flag / Red Flag Game: What Brands Get Wrong (and Right)32:00 – Why TikTok's Driving Advocacy, And Instagram Isn't36:00 – The Platform Breakdown: What's Working, What's Next41:00 – How to Really Build Brand Advocacy (It's Not a Coupon Code)Rate & review Building Brand Advocacy:Apple PodcastsSpotifyConnect with Gabe:On LinkedInOn MCoBeauty's Instagram (US)

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has rejected Capricor's therapy for Duchenne Muscular Dystrophy (DMD), causing shares to plunge due to insufficient evidence of effectiveness for cardiomyopathy associated with DMD. Lilly and Sarepta also received Complete Response Letters (CRLs) for their therapies. Moderna has won full approval for its COVID-19 vaccine for higher-risk kids, while Pacira has cut staff in San Diego. The FDA has released a cache of CRLs, providing insights into the journeys to market for various drugs. AbbVie has acquired Ichnos Glenmark's lead myeloma antibody, and Ultragenyx's stock plummeted after a late-stage trial disappointment. Kennedy postponed a preventive care panel meeting after a Supreme Court win. Transitioning from one piece of news to the next, let's move on to the webinar exploring digitization strategies for drug development. Stay tuned for more updates in the pharmaceutical industry.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Kalvista has received approval for the first on-demand hereditary angioedema pill after facing challenges with the FDA. Meanwhile, Robert F. Kennedy Jr. has made significant cuts and rehires at the Department of Health and Human Services. Upcoming biopharma milestones to watch include developments in obesity and rare genetic diseases, as well as therapies targeting the TIGIT space. Drug developers are exploring digitization strategies to optimize processes and embrace technology in the development journey amidst a busy buyout period in the pharmaceutical industry.Transitioning to the next news, the text discusses four therapies targeting TIGIT that are still holding on in a troubled space where many others have failed. It also highlights the potential of using AI and genetics to reduce adverse drug reactions and restore public trust in the pharmaceutical industry. Additionally, it mentions the FDA's decision to remove risk evaluation and mitigation strategies for certain cell and gene therapies, as well as recent developments in ultrarare therapies, cancer treatments, and regulatory changes. The text provides information on the HHS overhaul by the numbers, including rehiring hundreds of employees but still operating with reduced staff.

Two Enterprise Ireland-backed companies have won funding approvals of up to €18.75m in the latest competition under Horizon Europe's European Innovation Council (EIC) Accelerator Programme. The two successful companies are CroíValve and Lios. Enterprise Ireland leads the National Support Network for Horizon Europe which helps entrepreneurs to compete and win funding in EIC competitions. To date, 28 Irish companies have secured approvals totalling €175.5m under the EIC Accelerator Programme since the beginning of Horizon Europe in 2021. Trinity College Dublin spin-out company CroíValve is a clinical-stage medical device company focused on developing a minimally invasive device for the treatment of a severe cardiac disease called tricuspid regurgitation. CroíValve's DUO Tricuspid Coaptation Valve system will enable a non-surgical solution for the condition as currently less than one percent of elderly patients receive surgical treatment due to the risks involved in this population. CroíValve previously received funding under the Disruptive Technologies Innovation Fund which is administered by Enterprise Ireland and supports research collaboration to drive disruptive technology development. Lios, a pioneer in acoustic advanced materials technology, is a Dublin company with strong Sligo roots. SoundBounce is an advanced acoustic material developed by Lios that works better than traditional sound dampening materials. Transport, home appliances, power generation, and construction are among the major industries seeking to reduce noise levels. Part of the EU's Horizon Europe 2021-2027 Research and Innovation Programme, the EIC Accelerator Programme provides transformational funding to high-potential, high-risk start-ups, scale-ups and SMEs. Approvals include grant funding of up to €2.5 million combined with an equity investment ranging from €0.5 to €10 million in a blended finance offer. 959 applications were submitted to this latest competition with 150 companies subsequently selected for interview resulting in a total of 40 funding awards to 16 countries. The 40 companies were allocated funding of up to €229m in a combination of grants and equity investments. Almost one third of the selected companies were led by a woman in a key leadership role such as CEO, CTO or CSO. Minister of State for Trade Promotion, AI and Digital Transformation Niamh Smyth TD said: "Today's announcement is testament to the research and innovation capability of Irish companies and the vibrancy of the start-up and commercialisation eco-system. Collaboration between Higher Education, state agencies, investors, and business creates a pathway to success, and the government, through Enterprise Ireland, is committed to helping enterprises like Lios and CroíValve to realise their commercial potential. This announcement provides significant funding to support these companies to bring their innovations to the global market, and I wish both every success for the future." Jenny Melia, CEO Designate, Enterprise Ireland, said: "I'd like to congratulate Lios and CroíValve on their successful applications to the highly competitive EIC Accelerator programme. Both companies, working with the EIC, will be able to enhance their entrepreneurial capability and get the critical support required at this juncture in their development and scaling journey. It is particularly welcome to see that both projects have a female-inclusive leadership team which supports Enterprise Ireland's strategic ambition to increase the participation of women in entrepreneurship and business leadership." Lucy O'Keeffe, Co-Founder & CEO, CroíValve said: "Securing European Innovation Council (EIC) funding is very impactful in supporting full alignment of our novel technology with this complex patient population, along with expansion of clinical validation of our DUO System. There is a real unmet clinical need to provide a scalable treatment option for the heterogeneous patient population with tricuspi...

Top tips on how to secure a mortgage as approvals hit record levels. Telling us all was Martina Hennessy, Managing Director of Doddl.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC has reinstated around 460 employees who were previously fired, with the rehired staff working on viral disease prevention efforts and sexual health testing labs. This comes amid protests and shake-ups at the agency, including the overhaul of the vaccine advisory committee. Experts are concerned about newly appointed members, some of whom are known anti-vaxxers, potentially relitigating recommendations. Sen. Bill Cassidy is being urged to step up in response to these concerns.In other news, NuVation has received FDA approval for its oral lung cancer drug, Biontech has acquired CureVac in a $1.25 billion all-stock deal, and RFK Jr. has named new CDC vaccine advisors following a "clean sweep." Additionally, InVitro Cell Research is focused on discovering interventions to slow aging and prevent age-related diseases and is hiring scientists. The newsletter also includes information on layoffs at Genentech and Vertex.RFK Jr. has named eight new members to the CDC vaccine committee, replacing the 17 members he removed earlier in the week. The new choices seem to align with Kennedy's anti-vaccine views, causing concern among analysts. The HHS secretary's decision to appoint these scientists has raised questions about the committee's future direction.

On episode 844 of WHAT THE TRUCK?!? Dooner is catching up with SearchCarrier's Garrett Allen. His new site allows you to easily look up any carrier and see how often it's been put out of service, inspected and more. We're also diving into his blitz week dashboard to break down this year's top violations. Konexial's Jerry D'Addesi on the latest in AI load matching, double broker prevention and edge computing. Is the FMCSA starting to take freight fraud more seriously? After FMCSA's identity verification became mandatory in April 2025, published authority counts dropped by over 50%. We'll take a look at the numbers.  And in headlines: tariffs on, tariffs off; fast food restaurants vs fleet sizes; excessive LEGO sets and more.  Chapters 3:04 New authority approvals down 50% 5:19 Tariffs on, tariffs off, tariffs on 8:16 Fleet sizes vs. fast food restaurant locations 10:52 Konexial | Jerry D'Addesi 16:54 FreightTech innovations | Jerry D'Addesi 20:15 Too much LEGO 22:40 SearchCarriers | Garrett Allen 27:41 Blitz week breakdown | Garrett Allen Catch new shows live at noon EDT Mondays, Wednesdays and Fridays on FreightWaves LinkedIn, Facebook, X or YouTube, or on demand by looking up WHAT THE TRUCK?!? on your favorite podcast player and at 5 p.m. Eastern on SiriusXM's Road Dog Trucking Channel 146. Watch on YouTube Check out the WTT merch store Visit our sponsor Subscribe to the WTT newsletter Apple Podcasts Spotify More FreightWaves Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

On episode 844 of WHAT THE TRUCK?!? Dooner is catching up with SearchCarrier's Garrett Allen. His new site allows you to easily look up any carrier and see how often it's been put out of service, inspected and more. We're also diving into his blitz week dashboard to break down this year's top violations. Konexial's Jerry D'Addesi on the latest in AI load matching, double broker prevention and edge computing. Is the FMCSA starting to take freight fraud more seriously? After FMCSA's identity verification became mandatory in April 2025, published authority counts dropped by over 50%. We'll take a look at the numbers.  And in headlines: tariffs on, tariffs off; fast food restaurants vs fleet sizes; excessive LEGO sets and more.  Chapters 3:04 New authority approvals down 50% 5:19 Tariffs on, tariffs off, tariffs on 8:16 Fleet sizes vs. fast food restaurant locations 10:52 Konexial | Jerry D'Addesi 16:54 FreightTech innovations | Jerry D'Addesi 20:15 Too much LEGO 22:40 SearchCarriers | Garrett Allen 27:41 Blitz week breakdown | Garrett Allen Catch new shows live at noon EDT Mondays, Wednesdays and Fridays on FreightWaves LinkedIn, Facebook, X or YouTube, or on demand by looking up WHAT THE TRUCK?!? on your favorite podcast player and at 5 p.m. Eastern on SiriusXM's Road Dog Trucking Channel 146. Watch on YouTube Check out the WTT merch store Visit our sponsor Subscribe to the WTT newsletter Apple Podcasts Spotify More FreightWaves Podcasts Learn more about your ad choices. Visit megaphone.fm/adchoices

There's changes happening in the construction sector. Construction Minister Chris Penk is launching the country's first fully independent residential building consent authority - with approval subject to certain conditions being met. The privately-owned company, supported by the government, promises to issue building consents within 10 working days for eligible residential projects. Penk told Mike Hosking it's another option alongside local councils. He says initially it will be too small to take on all the work council does, but it might be able to scale up depending on what the appetite is. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.At a recent U.S. Senate hearing, Health and Human Services Secretary was questioned about cuts being made to the department and his stance on endorsing the measles vaccine during a growing outbreak. The hearing was tense at times, with RFK Jr. firm on supporting the cuts but wavering on his stance on the MMR vaccine. AbbVie's ADC received accelerated approval for lung cancer treatment, FDA delays decision on Biohaven's application, and chaos ensues at the FDA's advisory committee planning office after workforce cuts. Sino Biological offers solutions for autoimmune disease research, with reagents for nearly 50 diseases. Novo Nordisk has invested $2.4 billion in a new oral obesity drug through a deal with Septerna, aiming to catch up with competitors in the oral weight loss space. AbbVie has committed $335 million upfront in a partnership with Adarx Pharmaceuticals for siRNA research, while GSK has abandoned a TIGIT therapy and instead acquired rights to a liver drug from Boston Pharmaceuticals for potential $2 billion deal. This news highlights the ongoing developments and investments in the pharmaceutical industry.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson's, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny. 

Dr. Jonathan Howard and Wendy Orent examine the alarming elevation of wellness influencer Casey Means as Surgeon General nominee, despite lacking a medical license or conventional medical credibility. They delve into Vinay Prasad's appointment as head of vaccine regulation, scrutinizing his past critiques of RCT deficiencies—and the impossible standards he now sets for himself. The episode also investigates the troubling rise of an autism registry, likened to authoritarian categorization, and NIH's internal collapse under Jay Bhattacharya, whose leadership is marked by mass layoffs and denial of responsibility. With science policy veering into cronyism, dismantling, and performative governance, the episode argues that we're witnessing a historic erosion of public health leadership—led not by scientists, but social media provocateurs. Connect with us further on https://sciencebasedmedicine.org/author/jonathanhoward/  The Fine Print The content presented in the "We Want Them Infected" Podcast and associated book is intended for informational and educational purposes only.  The views and opinions expressed by the speakers, hosts, and guests on the podcast do not necessarily reflect the views of the creators, producers, or distributors. The information provided in this podcast should not be considered as a substitute for professional medical, scientific, or legal advice. Listeners and readers are encouraged to consult with relevant experts and authorities for specific guidance and information. The creators of the podcast and book have made reasonable efforts to ensure that the information provided is accurate and up to date. However, as the field of medical science and the understanding of the COVID-19 pandemic continue to evolve, there may be new developments and insights that are not covered in this content. The creators are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. They disclaim any liability for any loss, injury, or damage incurred by individuals who rely on the content. Listeners and readers are urged to use their judgment and conduct their own research when interpreting the information presented in the "We Want Them Infected" podcast and book. It is essential to stay informed about the latest updates, guidelines, and recommendations related to COVID-19 and vaccination from reputable sources, such as government health agencies and medical professionals. By accessing and using the content, you acknowledge and accept the terms of this disclaimer. Please consult with appropriate experts and authorities for specific guidance on matters related to health, science, and the COVID-19 pandemic.

U.S. Ties Trade Pressure to Starlink Approvals in Push Against China

FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.